Table A4.
Pertuzumab Naive (n = 13) |
Pertuzumab-Experienced (n = 51) | Overall (n = 64) |
|||||
---|---|---|---|---|---|---|---|
2013–2014 (n = 11) |
2015–2016 (n = 16) |
2017–2018 (n = 16) |
2019 (n = 8) |
p-Value | |||
Median age, years (IQR) | 63 (59–78) | 58 (54–68) | 63 (53–70) | 62 (54–69) | 62 (57–67) | 0.897 | 62 (54–69) |
Metastatic status, n (%) | 0.323 | ||||||
De novo | 6 (46) | ≤5 (<46) | ≤5 (<32) | 9 (56) | 6 (75) | 33 (52) | |
Recurrent | 7 (54) | 8 (73) | 7 (44) | 7 (44) | ≤5 (<63) | 31 (48) | |
Median BMI, kg/m2 (IQR) | 25 (22–33) | 26 (24–28) | 30 (26–31) | 26 (24–31) | 24 (22–27) | 0.243 | 27 (23–31) |
BMI categorization, n (%) | 0.533 | ||||||
Underweight (18.5 kg/m2) | ≤5 (<39) | ≤5 (<46) | 0 | 0 | 0 | ≤5 (<8) | |
Normal (19.5–24.9 kg/m2) | 6 (46) | ≤5 (<46) | ≤5 (<32) | 7 (44) | ≤5 (<63) | 24 (39) | |
Overweight (25.0–29.9 kg/m2) | ≤5 (<39) | ≤5 (<46) | ≤5 (<32) | ≤5 (<32) | ≤5 (<63) | 17 (28) | |
Obese (≥30 kg/m2) | ≤5 (<39) | ≤5 (<46) | 7 (50) | ≤5 (<32) | ≤5 (<63) | 18 (30) | |
Unknown | 0 | ≤5 (<46) | ≤5 (<32) | 0 | 0 | ≤5 (<8) | |
Hormone receptor status, n (%) | 0.495 | ||||||
Positive | 7 (54) | 8 (73) | 13 (81) | 12 (75) | ≤5 (<63) | 44 (69) | |
Negative | ≤5 (<39) | ≤5 (<46) | ≤5 (<32) | ≤5 (<32) | ≤5 (<63) | 19 (30) | |
Unknown | ≤5 (<39) | 0 | 0 | 0 | 0 | ≤5 (<8) | |
Practice setting | 0.028 | ||||||
Academic | ≤5 (<39) | 0 | 0 | 0 | ≤5 (<63) | ≤5 (<8) | |
Community-based | 12 (92) | 11 (100) | 16 (100) | 16 (100) | 6 (75) | 61 (95) | |
Median number of metastatic sites, n (IQR) | 2 (1–3) | 3 (3–4) | 4 (3–5) | 3 (2–5) | 4 (1–5) | 0.161 | 3 (2–5) |
Metastatic site, n (%) | |||||||
Bone | 8 (62) | 8 (73) | 12 (75) | 12 (75) | ≤5 (<63) | 0.905 | 45 (70) |
Visceral | 7 (54) | 7 (64) | 14 (88) | 11 (69) | ≤5 (<63) | 0.348 | 44 (69) |
Brain | ≤5 (<39) | ≤5 (<46) | 10 (62) | 8 (50) | ≤5 (<63) | 0.790 | 32 (50) |
Liver | ≤5 (<39) | ≤5 (<46) | 10 (62) | 8 (50) | ≤5 (<63) | 0.139 | 29 (45) |
Distant lymph node | ≤5 (<39) | ≤5 (<46) | 6 (38) | 9 (56) | ≤5 (<63) | 0.147 | 27 (42) |
Lung | 6 (46) | ≤5 (<46) | 8 (50) | ≤5 (<32) | ≤5 (<63) | 0.873 | 27 (42) |
Non-brain CNS | 0 | ≤5 (<46) | 0 | ≤5 (<32) | 0 | 0.176 | ≤5 (<8) |
Other | 0 | ≤5 (<46) | 0 | ≤5 (<32) | ≤5 (<63) | 0.108 | ≤5 (<8) |
Prior treatments, n (%) | |||||||
One prior treatment line | 13 (100) | 11 (100) | 16 (100) | 16 (100) | 8 (100) | NA | 64 (100) |
HER2-targeted treatments | 13 (100) | 11 (100) | 16 (100) | 16 (100) | 8 (100) | NA | 64 (100) |
Pertuzumab | 0 | 11 (100) | 16 (100) | 16 (100) | 8 (100) | NA | 51 (80) |
Trastuzumab | 13 (100) | 11 (100) | 16 (100) | 16 (100) | 8 (100) | NA | 64 (100) |
T-DM1 | 0 | ≤5 (<46) | 0 | 0 | 0 | 0.297 | ≤5 (<8) |
Time from mBC diagnosis to lapatinib initiation, months | |||||||
Median (IQR) | 11 (7–16) | 8 (7–17) | 14 (11–19) | 17 (13–23) | 25 (15–29) | 0.026 | 14 (9–20) |
Mean (SD) | 12 (7) | 11 (7) | 16 (9) | 18 (8) | 24 (13) | 0.026 | 16 (9) |
Index year, n (%) | NA | ||||||
2013–2014 | 6 (46) | 11 (100) | 0 | 0 | 0 | 17 (27) | |
2015–2016 | ≤5 (<39) | 0 | 16 (100) | 0 | 0 | 18 (28) | |
2017–2018 | ≤5 (<39) | 0 | 0 | 16 (100) | 0 | 19 (30) | |
2019 | ≤5 (<39) | 0 | 0 | 0 | 8 (100) | 10 (16) |
a Date on or prior to 31 December 2019, when treatment with lapatinib was initiated. b Patients who received 2L lapatinib. 2L = second-line; BMI = body mass index; CNS = central nervous system; DLN = distant lymph node; HER2 = human epidermal growth factor receptor 2; IQR = interquartile range; mBC = metastatic breast cancer; SD = standard deviation; T-DM1 = trastuzumab emtansine.